These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32898584)

  • 1. A dengue type 2 reporter virus assay amenable to high-throughput screening.
    Li LH; Kaptein SJF; Schmid MA; Zmurko J; Leyssen P; Neyts J; Dallmeier K
    Antiviral Res; 2020 Nov; 183():104929. PubMed ID: 32898584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a stable luciferase dengue virus for high-throughput screening.
    Zou G; Xu HY; Qing M; Wang QY; Shi PY
    Antiviral Res; 2011 Jul; 91(1):11-9. PubMed ID: 21575658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue virus replicons: production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity.
    Massé N; Davidson A; Ferron F; Alvarez K; Jacobs M; Romette JL; Canard B; Guillemot JC
    Antiviral Res; 2010 Jun; 86(3):296-305. PubMed ID: 20307577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening using dengue virus reporter genomes.
    Fischl W; Bartenschlager R
    Methods Mol Biol; 2013; 1030():205-19. PubMed ID: 23821271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Screening Assays for Dengue Antiviral Drug Development.
    Jabanathan SG; Xuan LZ; Ramanathan B
    Methods Mol Biol; 2021; 2296():279-302. PubMed ID: 33977455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the mode of action of a potent dengue virus capsid inhibitor.
    Scaturro P; Trist IM; Paul D; Kumar A; Acosta EG; Byrd CM; Jordan R; Brancale A; Bartenschlager R
    J Virol; 2014 Oct; 88(19):11540-55. PubMed ID: 25056895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-throughput assay using dengue-1 virus-like particles for drug discovery.
    Qing M; Liu W; Yuan Z; Gu F; Shi PY
    Antiviral Res; 2010 May; 86(2):163-71. PubMed ID: 20153777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
    Chiu W; Schepers J; Francken T; Vangeel L; Abbasi K; Jochmans D; De Jonghe S; Thibaut HJ; Thiel V; Neyts J; Laporte M; Leyssen P
    Antiviral Res; 2023 Feb; 210():105506. PubMed ID: 36565756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-based antiviral assays for screening and profiling inhibitors against dengue virus.
    Gong EY; Clynhens M; Ivens T; Lory P; Simmen K; Kraus G
    Methods Mol Biol; 2013; 1030():185-94. PubMed ID: 23821269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening.
    Zhang ZR; Zhang HQ; Li XD; Deng CL; Wang Z; Li JQ; Li N; Zhang QY; Zhang HL; Zhang B; Ye HQ
    Antiviral Res; 2020 Oct; 182():104884. PubMed ID: 32750466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms.
    Kato F; Hishiki T
    Viruses; 2016 May; 8(5):. PubMed ID: 27164125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.
    Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R
    Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying initiation and elongation inhibitors of dengue virus RNA polymerase in a high-throughput lead-finding campaign.
    Smith TM; Lim SP; Yue K; Busby SA; Arora R; Seh CC; Wright SK; Nutiu R; Niyomrattanakit P; Wan KF; Beer D; Shi PY; Benson TE
    J Biomol Screen; 2015 Jan; 20(1):153-63. PubMed ID: 25252731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells.
    Beesetti H; Tyagi P; Medapi B; Krishna VS; Sriram D; Khanna N; Swaminathan S
    Antivir Ther; 2018; 23(5):385-394. PubMed ID: 29583121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Versatile Reporter System To Monitor Virus-Infected Cells and Its Application to Dengue Virus and SARS-CoV-2.
    Pahmeier F; Neufeldt CJ; Cerikan B; Prasad V; Pape C; Laketa V; Ruggieri A; Bartenschlager R; Cortese M
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33257477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro.
    Schoggins JW; Dorner M; Feulner M; Imanaka N; Murphy MY; Ploss A; Rice CM
    Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14610-5. PubMed ID: 22908290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel Dengue-1 virus replicon system expressing secretory Gaussia luciferase for analysis of viral replication and discovery of antiviral drugs.
    Kato F; Kobayashi T; Tajima S; Takasaki T; Miura T; Igarashi T; Hishiki T
    Jpn J Infect Dis; 2014; 67(3):209-12. PubMed ID: 24858611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of inhibitors of dengue viral replication using replicon cells expressing secretory luciferase.
    Kato F; Nio Y; Yagasaki K; Suzuki R; Hijikata M; Miura T; Miyazaki I; Tajima S; Lim CK; Saijo M; Takasaki T; Hishiki T
    Antiviral Res; 2019 Dec; 172():104643. PubMed ID: 31678478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library.
    Hernandez-Morales I; Geluykens P; Clynhens M; Strijbos R; Goethals O; Megens S; Verheyen N; Last S; McGowan D; Coesemans E; De Boeck B; Stoops B; Devogelaere B; Pauwels F; Vandyck K; Berke JM; Raboisson P; Simmen K; Lory P; Van Loock M
    Antiviral Res; 2017 Nov; 147():149-158. PubMed ID: 29037976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.